



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/539,637	04/25/2006	Lars Bohlin	1510-1108	8577

466 7590 01/30/2007
YOUNG & THOMPSON
745 SOUTH 23RD STREET
2ND FLOOR
ARLINGTON, VA 22202

EXAMINER

YOUNG, HUGH PARKER

ART UNIT	PAPER NUMBER
----------	--------------

1654

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
31 DAYS	01/30/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No.		Applicant(s)	
	10/539,637		BOHLIN ET AL.	
	Examiner		Art Unit	
	Hugh P. Young		1654	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-14 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-14 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☒ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. ____. |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____. |

DETAILED ACTION

This is the first Office action on application number 10,539,637. There are fourteen claims pending, all of which are the subject of this restriction requirement.

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-8 and 12, drawn to an encrustation inhibiting agent comprising a peptide chosen from one declared peptide sequence of SEQ ID NOS: 1-5; and a device, object or organism protected by the agent.

Should Applicant elect Group I, one peptide sequence should be chosen for examination. This is not a species election of peptide from a genus but is an election of an invention under 35 U.S.C. 121.

Group II, claims 9, 10, and 14, drawn to an extract of violets and a device, object or organism protected from encrustation by the extract.

Group III, claim 11, drawn to a method of using a peptide elected from SEQ ID NOS: 1-5 to inhibit encrustation growth.

Should Applicant elect Group III, one peptide sequence should be chosen for examination. This is not a species election of peptide from a genus but is an election of an invention under 35 U.S.C. 121.

Group IV, claim 13, drawn to a method of using an extract of violets to inhibit encrustation growth.

2. The inventions listed as Groups I - IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or

Art Unit: 1654

corresponding special technical features for the following reasons: The special technical feature of the claims in the instant application are cyclic peptides of the cyclotide type, derived from extracts of violets and related plant species, the compounds to be used as inhibitors of biological growth on surfaces. The cyclotides are known in the art, as described by Craik et al. (1999), Plant cyclotides: a unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J. Molec. Biol. 294: 1327-1336. Craik et al. discuss the fundamental chemistry and biological functions of the cyclotides, including cycloviolacin 01 and kalata B1. The use of cyclopsychotides is described by Budny et al. (2002) in U.S. Patent Application Publication US 2002/0037260 A1, published March 28, 2002. Budny et al. disclose cyclopsychotides as being antimicrobial peptides in paragraphs [0067] and [0068], line 7. These peptides are claimed as components of an ophthalmic composition in claims 21 and 24, page 10. The claims of the instant application thus lack a special technical feature that would constitute a contribution over the prior art.

3. Claims 1-6 and 12 comprise peptides that differ in structure because the sequences provided in these claims comprise non-conservative amino acid substitutions. Thus, sequences without a divulged core structure that explains the peptides' functions or properties have been claimed for Invention I and are necessary to practice Invention II. Therefore, the peptide sequences (SEQ ID NOS: 1-5) are considered to be patentably distinct. If either Invention I or III is elected, it will be examined only insofar as it pertains to the single sequence listed therein and selected therefrom. This is NOT a species election, but rather an invention election under

Art Unit: 1654

Section 121, 35 USC. If sequences of the other inventions happen to be found in the search of the selected invention, the examiner will rejoin the invention comprising the found sequence in accordance with *in re Ochiai*. Rejoinder is possible if Applicant provides a single and specific representative subsequence and states that the sequences of SEQ ID NOS: 1-5 are **not patentably distinct**, given a disclosed unifying common feature. Applicant is informed that if the specified sequence is found that all or a specified subset of sequences are obvious over that prior art sequence.

4. Furthermore, the instantly claimed inventions are to different categories of invention; however, they do not meet the following requirements of 37 CFR 1.475, wherein they instantly have multiple products and multiple methods of using to make medicaments.

37 CFR § 1.475 states: ...

(b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:

(1) A product and a process specially adapted for the manufacture of said product; or

(2) A product and process of use of said product; or

(3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or

(4) A process and an apparatus or means specifically designed for carrying out the said process; or

(5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.

(c) If an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present...

Art Unit: 1654

(e) The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.

Annex B, Part I(f) of the Administrative Instructions under PCT states that, "wherein a single claim defines alternatives (chemical or non-chemical)...the requirement of a technical interrelationship and the same or corresponding special technical features as defined in Rule 13.2, shall be considered to be met when the alternatives are of a similar nature."

The alternatives must comply with subsections (i)(A) and one of either (i)(B)(1) or (i)(B)(2), which requires that, "all alternatives have a common property or activity" and "a common structure is present, i.e., a significant structural element is shared by all of the alternatives" (B)(1) or "in cases where the common structure cannot be the unifying criteria, all alternatives belong to a recognized class of chemical compounds in the art to which the invention pertains." (B)(2).

In the instant case, the peptides of claims 3-5 require that the compounds have the same activity/function (ACE inhibition), satisfying requirement (A). However, the claims fails to satisfy either (B)(1) or (B)(2). The claims recite structures that as defined by the claim limitations are open to compounds that do not necessarily share a common core, thus failing to meet the requirements of (B)(1).

Further, in looking to subsection (f)(iii), it is stated that 'recognized class of chemical compounds' means that, "there is an expectation from the knowledge in the art that members of the class will behave in the same way in the context of the claimed invention. In other words, each member could be substituted one for the other, with the expectation that the same intended result would be achieved." One of skill in the art would not recognize these divergent peptides to function in the context of the instantly claimed invention. Thus, the claim fails to meet the requirement of (B)(2).

Species election requirement

5. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. The species are as follows:

The species of plant from which extracts will be obtained, claimed in claim 9, Group II and claim 13, Group IV.

Should applicants elect as their invention Groups II or IV, they must elect a single species of plant as their species.

6. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

7. Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

Inventorship

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Rejoinder

9. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP

Art Unit: 1654

§ 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Conclusion

10. No claims are allowed.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hugh P. Young whose telephone number is (571)-272-4988. The examiner can normally be reached on 8:00 AM - 5:00 PM.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1654

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Hugh P. Young Ph.D.

GAU 1654



JON WEBER
SUPERVISORY PATENT EXAMINER